Advances in the treatment of hairy-cell leukaemia (Q35062368)

6 August 2017

1 reference

title

Advances in the treatment of hairy-cell leukaemia (English)

1 reference

6 August 2017

1 reference

Ulrich Mey

1 reference

6 August 2017

John Strehl

1 reference

6 August 2017

Marcus Gorschlüter

1 reference

6 August 2017

Carsten Ziske

1 reference

6 August 2017

Axel Glasmacher

1 reference

6 August 2017

Hans Pralle

1 reference

6 August 2017

Ingo Schmidt-Wolf

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Lancet Oncology Commission

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

86-94

1 reference

Splenectomy for hairy cell leukemia. A clinical review of 63 patients

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Splenectomy in hairy cell leukemia: A retrospective multicenter analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Alpha interferon for induction of remission in hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

The optimal management of hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Pentostatin induces durable remissions in hairy cell leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Efficacy of 2'-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Durable complete remissions after 2'-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Long term outcome of patients with hairy cell leukemia treated with pentostatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Pentostatin in the treatment of advanced hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Immunosuppressive effects of pentostatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Infectious and immunosuppressive complications of purine analog therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Efficacy of rituximab in hairy cell leukemia treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Long-term follow-up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long‐term follow‐up study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Second cancer risk in hairy cell leukemia: analysis of 350 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Risk of second cancer in patients with hairy cell leukemia: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900980-X

7 January 2021

10.1016/S1470-2045(03)00980-X

Identifiers

DOI

1 reference

6 August 2017

1 reference